Sanofi launches vitamins in China
January 30, 2010
The long walk from Sanofi-Aventis in China continues. The French group, who already makes drugs against diabetes and markets vaccines and treatments including cardiovascular disease and cancer, tackling the local market for vitamins and mineral supplements. "This segment of the consumer health more important in China," said the laboratory, announced Friday that an alliance with Minsheng laboratory. They will create a joint venture, which will be majority Sanofi. His new partner, said the group is well established in this key market niche by "his brand of multivitamin 21 Super-Vita.
Tripling sales
Fourth World Laboratory, Sanofi-Aventis begins to reap the benefits of its presence in the Middle Kingdom. In 1982 he was one of the first to take up with the launch of its anti-arrhythmic Cordarone.The start was winded, like most foreign groups. In 2005, sales of AstraZeneca, a number of laboratories in the Western Middle Kingdom does not exceed 250 million euros and those of Sanofi-Aventis were limited to 200 million euros.
Since then, sales of Sanofi in China almost tripled to 540 million euros over the first nine months of 2009.
Sanofi increases investment to increase production on site one hour payday loan . Eager to win locally on the diabetes market facing Norsdik Novo Nordic, the pharmaceutical group has invested last year 90 million dollars (600 million RMB) in its production site in Beijing Lantus.
Sanofi also has 64 million from its plant vaccines against influenza in Shenzhen.The leader of this group intends to extend its leadership in this field in China. The market, estimated at 1 billion dollars, is locked by Chinese manufacturers. They sell three quarters of vaccines. Sanofi holds 10% market share.
"Sanofi-Aventis in this region a real strategy, a comprehensive approach," Eric appreciates the Berrigaud, financial analyst at Raymond James. The laboratory operates in China, soon to third world drug market, the same strategy of diversification and globally.
The healthcare consumer is one of the five pillars of growth identified last year by its new chief executive Chris Viehbacher. World number five on this growing market, Sanofi-Aventis multiplies acquisitions.He announced in December the acquisition of the US Chattem 1.9 billion.
ALSO READ
"Sanofi-Aventis pushed his pawns in China
Sorry, comments for this entry are closed at this time.